| Table 1. |
Goals for CVD Risk Factor Management in Patients With Diabetes |
| Table 2. |
Diagnostic Testing for Coronary Heart Disease in Diabetes |
| Table 3. |
Definitions of Abnormalities in Albumin Excretion |
| Table 4. |
Albuminuria as a Predictor of Albuminuria Progression in Type 1 Diabetes |
| Table 5. |
Albuminuria as a Predictor of Albuminuria Progression in Type 2 Diabetes |
| Table 6. |
Likelihood of DKD According to Staging by GFR and Level of Albuminuria |
| Table 7. |
Albuminuria as a Predictor of DKD Progression, CVD, and Mortality in Type 1 Diabetes |
| Table 8. |
Albuminuria as a Predictor of DKD Progression, CVD, and Mortality in Type 2 Diabetes |
| Table 9. |
Relationship Between Albuminuria and Kidney Morphology in Type 1 Diabetes |
| Table 10. |
Relationship Between Kidney Function and Morphology in Type 1 Diabetes |
| Table 11. |
Relationship Between Albuminuria and Kidney Morphology in Type 2 Diabetes |
| Table 12. |
Relationship Between Kidney Function and Morphology in Type 2 Diabetes |
| Table 13. |
Predictive Value of Diabetic Retinopathy for Diagnosis of DKD in Biopsy Studies |
| Table 14. |
Strategies to Prevent Bleeding After Kidney Biopsy |
| Table 15. |
Observed Incidence of Acute Kidney Failure After PCI That Included Administration of Radiocontrast, Stratified by Baseline Serum Creatinine and Diabetes Status |
| Table 16. |
Effect of Interventions to Decrease the Risk of RCN in People With Diabetes and CKD Undergoing Angiographic Procedures |
| Table 17. |
Type of Radiocontrast Agent and Risk of RCN in Diabetes and/or CKD |
| Table 18. |
Preventive Strategies for RCN |
| Table 19. |
Effect of Glycemic Control on Kidney Function and Albuminuria in Type 1 Diabetes |
| Table 20. |
Effect of Glycemic Control on Kidney Function and Albuminuria in Type 2 Diabetes |
| Table 21. |
Effect of TZDs on Albuminuria, Glycemia, and Blood Pressure in Type 2 Diabetes |
| Table 22. |
Dosing Adjustments by CKD Stage for Drugs Used to Treat Hyperglycemia |
| Table 23. |
Insulin Preparations Categorized by Duration of Effect |
| Table 24. |
Clinically Relevant Interactions With Drugs Used to Treat Hyperglycemia |
| Table 25. |
ADA Standards for Assessment of Glycemic Control |
| Table 26. |
ADA Standards for Assessment of Retinopathy and Foot Care |
| Table 27. |
Hypertension and Antihypertensive Agents in DKD |
| Table 28. |
Doses of ACE Inhibitors and ARBs for Adults |
| Table 29. |
Prevalence of Hypertension in DKD |
| Table 30. |
Effect of Antihypertensive Agents on CKD and Hypertension in Type 1 and Type 2 Diabetes |
| Table 31. |
Effect of Different Blood Pressure Targets on CKD in Type 1 and Type 2 Diabetes |
| Table 32. |
Summary of Number of Antihypertensive Agents Required to Reach Target Blood Pressure |
| Table 33. |
Recommended Intervals for Follow-Up Evaluation of Blood Pressure, GFR, and Potassium |
| Table 34. |
Effect of Lipid-Lowering Treatments on Kidney Function and Albuminuria in Type 1 and Type 2 Diabetes |
| Table 35. |
Dosing Adjustments of Medicines to Treat Lipid Disorders in CKD |
| Table 36. |
NKF-KDOQI™ CPGs for Managing Dyslipidemia in CKD Stages 1 to 4 |
| Table 37. |
Effect of Low-Protein Diets on Mortality, Kidney Function, Albuminuria, and Risk Factors in Type 1 Diabetes |
| Table 38. |
Effect of Low-Protein Diets on Kidney Function, Albuminuria, and Risk Factors in Type 2 Diabetes |
| Table 39. |
Effect of Miscellaneous Diets on Kidney Function, Albuminuria, and Risk Factors in Type 1 Diabetes |
| Table 40. |
Effect of Miscellaneous Diets on Mortality, Kidney Function, Albuminuria, and Risk Factors in Type 2 Diabetes |
| Table 41. |
Effect of Fatty Acid Supplements on Kidney Function, Albuminuria, and Risk Factors in Type 1 and Type 2 Diabetes |
| Table 42. |
Key Studies Evaluating Effects of Dietary Protein Restriction or Other Alterations on Kidney Outcomes in Patients With Diabetes and CKD |
| Table 43. |
A Balanced Approach to Nutrition in CKD With or Without Diabetes: Macronutrient Composition and Mineral Content |
| Table 44. |
Effect of ACE Inhibitors on Mortality, CVD, Kidney Function, Albuminuria, and Miscellaneous Outcomes in Type 2 Diabetes |
| Table 45. |
Effect of ARBs on Mortality, Kidney Function, and Albuminuria in Type 2 Diabetes |
| Table 46. |
Effect of ARBs versus ACE Inhibitors on Kidney Function and Albuminuria in Type 2 Diabetes |
| Table 47. |
Effect of Miscellaneous Treatments on Mortality, Kidney Function, and Albuminuria in Type 2 Diabetes |
| Table 48. |
Summary of Steno Trial Multifaceted Intervention for Diabetes and CKD |
| Table 49. |
Proposed Mechanisms for Associations Between Obesity and CKD |
| Table 50. |
Countries With the Highest Numbers of Estimated Cases of Diabetes for 2000 and 2030. |
| Table 51. |
Plasma Blood Glucose and HbA1c Goals for Type 1 Diabetes by Age Group. |
| Table 52. |
Adverse Maternal and Child Outcomes in Pregnancies Complicated by Diabetes and CKD |
| Table 53. |
Predictors of Adverse Maternal and Child Outcomes in Pregnancies Complicated by Diabetes and CKD |
| Table 54. |
Management of Pregnant Women With Diabetes and CKD |
| Table 55. |
Systematic Reviews of Behavioral Studies in People With Diabetes |
| Table 56. |
Components and Principles of a Diabetes and CKD Self-Management Education Program |
| Table 57. |
Self-Management Principles |
| Table 58. |
Nutrient Composition of This Full-Day Meal Plan |
| Table 59. |
Topics for Which Systematic Reviews of Primary Studies Were Performed |
| Table 60. |
Format for Guidelines |
| Table 61. |
Rating the Strength of Guideline and CPR Statements |
| Table 62. |
Rating the Quality of Evidence |